Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

Equity Capital Markets

Jiangxi Institute of Biological Products / Equity Capital Markets

Jiangxi Institute of Biological Products (JIBP HK)

<ul>
<li>Jiangxi Institute of Biological Products, the largest provider and exporter of human tetanus antitoxins (TAT) in China, has launched its HK IPO consisting of 36M H shares.</li>
<li>The indicative offer price range has been fixed at HK$9.33–13.06 per share. The company intends to raise HK$473M, mainly to fund R&amp;D and construction and expansion of new facilities.</li>
<li>The subscription period will close on June 25, with shares expected to make trading debut on June 30. CICC, CMS, and Futu Securities are the joint sponsors to the issue.</li>
</ul>


Jiangxi Institute of Biological Products, the largest provider and exporter of human tetanus antitoxins (TAT) in China, has launched its HK IPO consisting of 36M H shares.
The indicative offer price range has been fixed at HK$9.33–13.06 per share. The company intends to raise HK$473M, mainly to fund R&amp;D and construction and expansion of new facilities.
The subscription period will close on June 25, with shares expected to make trading debut on June 30. CICC, CMS, and Futu Securities are the joint sponsors to the issue.


Jiangxi Biology IPO: Key Product Enjoys Global Market Leadership; Pipeline Lends Visibility